- Home
- Publications
- Publication Search
- Publication Details
Title
Potential serotonergic agents for the treatment of schizophrenia
Authors
Keywords
-
Journal
EXPERT OPINION ON INVESTIGATIONAL DRUGS
Volume 25, Issue 2, Pages 159-170
Publisher
Informa Healthcare
Online
2015-11-18
DOI
10.1517/13543784.2016.1121995
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Executive functioning in schizophrenia: Unique and shared variance with measures of fluid intelligence
- (2015) A.K. Martin et al. BRAIN AND COGNITION
- Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Encenicline, a Selective α7 Nicotinic Receptor Partial Agonist, in Single Ascending-dose and Bioavailability Studies
- (2015) Ann J. Barbier et al. CLINICAL THERAPEUTICS
- Targeting the Serotonin 5-HT7 Receptor in the Search for Treatments for CNS Disorders: Rationale and Progress to Date
- (2015) Agnieszka Nikiforuk CNS DRUGS
- Idalopirdine as a treatment for Alzheimer’s disease
- (2015) Daniela Galimberti et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Randomized Controlled Trials of Add-On Antidepressants in Schizophrenia
- (2015) Viacheslav Terevnikov et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Novel 5-HT5A receptor antagonists ameliorate scopolamine-induced working memory deficit in mice and reference memory impairment in aged rats
- (2015) Mayako Yamazaki et al. JOURNAL OF PHARMACOLOGICAL SCIENCES
- Social cognition, social competence, negative symptoms and social outcomes: Inter-relationships in people with schizophrenia
- (2015) Marc Kalin et al. JOURNAL OF PSYCHIATRIC RESEARCH
- The role of the serotonin receptor subtypes 5-HT1A and 5-HT7 and its interaction in emotional learning and memory
- (2015) Oliver Stiedl et al. Frontiers in Pharmacology
- THE 5-HT6 RECEPTOR ANTAGONIST LU AE58054 ALONE AND IN COMBINATION WITH DONEPEZIL POTENTIATES GAMMA OSCILLATIONS IN RAT MEDIAL PREFRONTAL CORTEX
- (2014) Maria Amat Foraster et al. Alzheimers & Dementia
- THE 5-HT6 ANTAGONIST LU AE58054 POTENTIATES THE EFFECTS OF ACETYLCHOLINESTERASE INHIBITION ON EXTRACELLULAR ACETYLCHOLINE LEVELS AND OSCILLATORY ACTIVITY IN THE RAT DORSAL HIPPOCAMPUS
- (2014) Kjartan Frisch Herrik et al. Alzheimers & Dementia
- A double-blind, placebo-controlled comparator study of LY2140023 monohydrate in patients with schizophrenia
- (2014) AnnCatherine M Downing et al. BMC Psychiatry
- Bipolar disorder: recent clinical trials and emerging therapies for depressive episodes and maintenance treatment
- (2014) Ricardo P. Garay et al. DRUG DISCOVERY TODAY
- ASP5736, a novel 5-HT5A receptor antagonist, ameliorates positive symptoms and cognitive impairment in animal models of schizophrenia
- (2014) Mayako Yamazaki et al. EUROPEAN NEUROPSYCHOPHARMACOLOGY
- Investigational drugs for anxiety in patients with schizophrenia
- (2014) Ricardo P Garay et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- Anti-anxiety effect of a novel 5-HT3receptor antagonist N-(benzo[d]thiazol-2-yl)-3-ethoxyquinoxalin-2-carboxamide (6k) using battery tests for anxiety in mice
- (2014) YeshwantVijay Kurhe et al. INDIAN JOURNAL OF PHARMACOLOGY
- Measurements of Response, Remission, and Recovery in Schizophrenia and Examples for Their Clinical Application
- (2014) Stefan Leucht JOURNAL OF CLINICAL PSYCHIATRY
- Unmet Needs in the Treatment of Schizophrenia
- (2014) Leslie Citrome JOURNAL OF CLINICAL PSYCHIATRY
- A 6-week randomized, double-blind, placebo-controlled, comparator referenced trial of vabicaserin in acute schizophrenia
- (2014) Joan H.Q. Shen et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Idalopirdine for Alzheimer's disease: written in the stars
- (2014) Lon S Schneider LANCET NEUROLOGY
- Safety and efficacy of idalopirdine, a 5-HT 6 receptor antagonist, in patients with moderate Alzheimer's disease (LADDER): a randomised, double-blind, placebo-controlled phase 2 trial
- (2014) David Wilkinson et al. LANCET NEUROLOGY
- On the Discovery and Development of Pimavanserin: A Novel Drug Candidate for Parkinson’s Psychosis
- (2014) Uli Hacksell et al. NEUROCHEMICAL RESEARCH
- Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission
- (2014) Gretchen L. Snyder et al. PSYCHOPHARMACOLOGY
- The role of 5-HT7 receptor antagonism in the amelioration of MK-801-induced learning and memory deficits by the novel atypical antipsychotic drug lurasidone
- (2013) Tomoko Horisawa et al. BEHAVIOURAL BRAIN RESEARCH
- Add-on clinical effects of selective antagonist of 5HT6 receptors AVN-211 (CD-008-0173) in patients with schizophrenia stabilized on antipsychotic treatment: pilot study
- (2013) Margarita A. Morozova et al. CNS SPECTRUMS
- Pimavanserin for the treatment of Parkinson's disease psychosis
- (2013) Joseph H Friedman EXPERT OPINION ON PHARMACOTHERAPY
- Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis
- (2013) Taro Kishi et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Meta-analysis of noradrenergic and specific serotonergic antidepressant use in schizophrenia
- (2013) Taro Kishi et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Lorcaserin and pimavanserin: emerging selectivity of serotonin receptor subtype–targeted drugs
- (2013) Herbert Y. Meltzer et al. JOURNAL OF CLINICAL INVESTIGATION
- Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: Randomized double-blind placebo-controlled study
- (2013) Mohammad-Reza Khodaie-Ardakani et al. JOURNAL OF PSYCHIATRIC RESEARCH
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis
- (2013) Stefan Leucht et al. LANCET
- Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial
- (2013) Jeffrey Cummings et al. LANCET
- Selective Serotonin 3 Receptor Antagonist Treatment for Schizophrenia: Meta-analysis and Systematic Review
- (2013) Taro Kishi et al. NEUROMOLECULAR MEDICINE
- A placebo-controlled study of tropisetron added to risperidone for the treatment of negative symptoms in chronic and stable schizophrenia
- (2013) Maryam Noroozian et al. PSYCHOPHARMACOLOGY
- Definition and description of schizophrenia in the DSM-5
- (2013) Rajiv Tandon et al. SCHIZOPHRENIA RESEARCH
- Pomaglumetad methionil: No significant difference as an adjunctive treatment for patients with prominent negative symptoms of schizophrenia compared to placebo
- (2013) Virginia L. Stauffer et al. SCHIZOPHRENIA RESEARCH
- 48-week efficacy and tolerability of treatment with SB-742457, a novel 5HT6 receptor antagonist, when added on to donepezil in subjects with mild-to-moderate Alzheimer's disease (AD)
- (2012) Gareth Maher-Edwards et al. Alzheimers & Dementia
- Short-Term Tropisetron Treatment and Cognitive and P50 Auditory Gating Deficits in Schizophrenia
- (2012) Xiang Yang Zhang et al. AMERICAN JOURNAL OF PSYCHIATRY
- Effect of 5-HT5A antagonists in animal models of schizophrenia, anxiety and depression
- (2012) Ferenc Kassai et al. BEHAVIOURAL PHARMACOLOGY
- Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010
- (2012) Joshua A Salomon et al. LANCET
- Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010
- (2012) Theo Vos et al. LANCET
- Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day
- (2012) Herbert Y. Meltzer et al. SCHIZOPHRENIA RESEARCH
- The effects of selective antagonists of serotonin 5-HT7 and 5-HT1A receptors on MK-801-induced impairment of learning and memory in the passive avoidance and Morris water maze tests in rats: Mechanistic implications for the beneficial effects of the novel atypical antipsychotic lurasidone
- (2011) Tomoko Horisawa et al. BEHAVIOURAL BRAIN RESEARCH
- Effects of the selective 5-HT7 receptor antagonist SB-269970 in animal models of psychosis and cognition
- (2011) Kerry A. Waters et al. BEHAVIOURAL BRAIN RESEARCH
- Animal models of schizophrenia
- (2011) CA Jones et al. BRITISH JOURNAL OF PHARMACOLOGY
- The role of serotonin receptors in the action of atypical antipsychotic drugs
- (2011) HY Meltzer et al. CURRENT OPINION IN PHARMACOLOGY
- Inverse agonism and its therapeutic significance
- (2011) Gurudas Khilnani et al. INDIAN JOURNAL OF PHARMACOLOGY
- Characterization of Vabicaserin (SCA-136), a Selective 5-Hydroxytryptamine 2C Receptor Agonist
- (2011) J. Dunlop et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- The effects of PRX-07034, a novel 5-HT6 antagonist, on cognitive flexibility and working memory in rats
- (2011) Eric G. Mohler et al. PSYCHOPHARMACOLOGY
- The Role of Ondansetron in the Treatment of Schizophrenia
- (2010) Allison C Bennett et al. ANNALS OF PHARMACOTHERAPY
- Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats
- (2010) Jorn Arnt et al. INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
- Animal models of cognitive dysfunction and negative symptoms of schizophrenia: Focus on NMDA receptor antagonism
- (2010) Joanna C. Neill et al. PHARMACOLOGY & THERAPEUTICS
- Combination of escitalopram and a 5-HT1A receptor antagonist selectively decreases the extracellular levels of dopamine in the nucleus accumbens relative to striatum through 5-HT2C receptor stimulation; suggestive of antipsychotic potential
- (2010) Nanna Hovelsø et al. PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR
- A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia
- (2010) Akihiro Shiina et al. Annals of General Psychiatry
- Effects of SB-269970, a 5-HT7 receptor antagonist, in mouse models predictive of antipsychotic-like activity
- (2009) Ruggero Galici et al. BEHAVIOURAL PHARMACOLOGY
- Cognitive Improvement by Activation of α7 Nicotinic Acetylcholine Receptors: From Animal Models to Human Pathophysiology
- (2009) Morten Thomsen et al. CURRENT PHARMACEUTICAL DESIGN
- 5-HT antagonists NAN-190 and SB 269970 block α2-adrenoceptors in the guinea pig
- (2009) Jaime Pei Pei Foong et al. NEUROREPORT
- Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo
- (2009) Atheir I. Abbas et al. PSYCHOPHARMACOLOGY
- Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders
- (2008) Atheir Abbas et al. EXPERT OPINION ON PHARMACOTHERAPY
- An update on the role of the 5-hydroxytryptamine6 receptor in cognitive function
- (2008) Kevin C.F. Fone NEUROPHARMACOLOGY
- The 5-HT3 receptor – the relationship between structure and function
- (2008) Nicholas M. Barnes et al. NEUROPHARMACOLOGY
- Added ondansetron for stable schizophrenia: A double blind, placebo controlled trial
- (2008) Shahin Akhondzadeh et al. SCHIZOPHRENIA RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started